Drugs heal, but they can also harm, and when a prescription drug causes serious injury the law treats it very differently from a defective device. A patient injured by a medication enters a framework shaped by the learned intermediary doctrine, by federal preemption rules that cut the opposite way from medical devices, and often by the machinery of mass litigation. These features make dangerous drug cases their own distinct corner of product liability. Warnings, FDA approval, and the brand-versus-generic distinction are what injury rights in this area depend on.
Dangerous Drug Claims and Their Theories
A dangerous drug claim generally rests on one of three theories: a design defect, a manufacturing defect, or a failure to warn. In practice, most modern drug cases turn on failure to warn, the allegation that the manufacturer knew or should have known of a risk and did not adequately disclose it. A design-defect theory argues the drug was unreasonably dangerous as formulated, and a manufacturing-defect theory addresses contamination or deviation in a particular batch. The failure-to-warn theory dominates because drug risks often emerge from how a known medication is labeled rather than from a flaw in a single dose.
The Learned Intermediary Doctrine
As with medical devices, warnings about a prescription drug generally run to the prescribing physician rather than the patient. Under the learned intermediary doctrine, a manufacturer ordinarily satisfies its duty to warn by adequately informing the prescriber, who is positioned to weigh the drug’s risks against the patient’s needs. The central question in a drug failure-to-warn case is therefore whether the warning to the physician was adequate, not whether the patient personally received it.
FDA Approval and Preemption: Why Drugs Differ from Devices
Here the contrast with medical devices is sharp. For devices that received rigorous premarket approval, federal law broadly preempts state claims. For prescription drugs, the U.S. Supreme Court reached the opposite conclusion. In Wyeth v. Levine, the Court held that FDA approval of a brand-name drug’s label does not, by itself, preempt a state failure-to-warn claim, because the manufacturer can unilaterally strengthen its label through the FDA’s “changes being effected” regulation and bears responsibility for its label at all times. So FDA approval is generally not a complete shield for a brand-name drug manufacturer.
Brand-Name Versus Generic Drugs
The preemption picture splits along the brand-versus-generic line:
- Brand-name drugs: under Wyeth v. Levine, state failure-to-warn claims generally are not preempted, because the manufacturer can update its own label.
- Generic drugs: under PLIVA v. Mensing, failure-to-warn claims generally are preempted, because federal law requires generics to match the brand-name label and they cannot unilaterally change it.
This distinction can be decisive, and it means the same injury from the same medication may face very different legal paths depending on whether the version taken was brand-name or generic.
The Reality of Mass Torts and MDLs
Dangerous drug claims frequently unfold not as solitary lawsuits but as part of mass litigation. When many people are injured by the same drug, federal cases are often consolidated through the Judicial Panel on Multidistrict Litigation into a single multidistrict litigation, or MDL, for coordinated pretrial proceedings before being resolved or returned. This structure handles common questions efficiently, though many viable claims also proceed individually in state court. For an injured person, this means a drug claim may join a larger coordinated effort rather than stand entirely alone.
Frequently Asked Questions
Can I sue if the FDA approved the drug?
For a brand-name drug, FDA approval generally does not by itself bar a state failure-to-warn claim, because the manufacturer can strengthen its label, as the Supreme Court held in Wyeth v. Levine.
Does it matter whether the drug was brand-name or generic?
Yes. Brand-name failure-to-warn claims generally are not preempted, while generic-drug failure-to-warn claims generally are preempted under PLIVA v. Mensing, because generics must match the brand label.
Who must be warned about a drug’s risks?
Under the learned intermediary doctrine, the manufacturer’s duty generally runs to the prescribing physician rather than to the patient directly, so the adequacy of the warning to the prescriber is central.
What is an MDL?
A multidistrict litigation consolidates many federal cases involving the same drug before one judge for coordinated pretrial proceedings. Many drug claims join an MDL, though some proceed individually in state court.
Dangerous drug claims turn on the learned intermediary doctrine, the brand-versus-generic preemption divide, and the mass-tort structure. A Georgia personal injury attorney can situate a specific drug injury within this framework.